Cystic Fibrosis Therapeutics in Major Developed Market Worth $4.0 Billion by 2019: Radiant Insights, Inc.
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 02/25/16 -- The cystic fibrosis market had a market value of more than USD 695 million in 2012 and is anticipated to rise drastically over the future period in the major 8 developed countries and will surpass USD 4.0 billion by 2019. Thus associates to a compounded annual growth rate of more than 30%.
Original treatment with disease-modifying mechanism of action is the main feature increasing the growth of the market in terms of value. The constructive effect of the market''s new applicant will counteract the effects of major patent failures throughout the estimated period.
The first ever cystic fibrosis therapy was CFTR (Cystic Fibrosis Transmembrane conductance Regulator) for treating the root reasons of the illness instead of the symptom. This resulted into the Patients'' enhanced help and value of life. Among CFTR modulator, Kalydeco was the first one to reach the market. This was in the market since 2012. It could treat only a tiny part of CF people, yet the market value had a major effect on it.
With the market entry of Ataluren & lumacaftor, the effect is going to be repetitive to a huge extent, because of the ability of it being used on a bigger number of the CF sufferers. Llumacaftor, Kalydeco, and early previous phase CFTR modulator are developed by Vertex Pharmaceuticals Inc. These are hence anticipated to be performing a major role in developing the forthcoming market.
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.02.2016 - 04:14 Uhr
Sprache: Deutsch
News-ID 1417607
Anzahl Zeichen: 3809
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cystic Fibrosis Therapeutics in Major Developed Market Worth $4.0 Billion by 2019: Radiant Insights, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Radiant Insights, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
